CTOs on the Move

Madrigal Pharmaceuticals

www.madrigalpharma.com

 
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Ronald Filippo
Chief Information Officer Profile
Dominic Labriola
Chief Data and Analytics Officer Profile
Nicole Rosenberger
Vice President, Head of Information Technology Profile

Jobs

Chief Information Security Officer

Madrigal Pharmaceuticals Conshohocken, PA

Chief Information Security Officer

Madrigal Pharmaceuticals Conshohocken, PA

Funding

Madrigal Pharmaceuticals raised $250M on 05/09/2022

Similar Companies

Ironshore Pharmaceuticals

Ironshore Therapeutics Inc. (formerly known as Highland Therapeutics Inc.) is a pharmaceutical company whose mission is to develop and commercialize first-in-class treatment options to improve the lives of patients and caregivers.

Shionogi USA Inc

Shionogi USA Inc is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Galleon Pharmaceutical

Galleon Pharmaceutical is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mallinckrodt

At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives. As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives. As a specialty pharmaceuticals leader, we develop, manufacture, market and distribute specialty pharmaceuticals and therapies. Within our areas of focus, we provide treatments to underserved patient populations within neurology, rheumatology, nephrology, pulmonology, and ophthalmology. Our expertise also extends into acute and critical care hospital products, as well as our broad portfolio of generic prescription medicines, and active pharmaceutical ingredients. Together, we`re helping shape the future of the specialty pharmaceuticals industry by leveraging the values our founders instilled nearly 150 years ago – quality, integrity and service. Mallinckrodt Pharmaceuticals provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity, national origin, age, disability, veteran status, or genetics. In addition to federal law requirements, Mallinckrodt Pharmaceuticals complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation and training.

Deciphera

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.